US · INCY · BIOTECHNOLOGY
Incyte Corporation (INCY) intrinsic value and stock valuation
$114.63as of 2026-11-21 · Mkt cap 24.44B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Incyte Corporation DCF and intrinsic value
InvestorsCraft values INCY with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from INCY’s statements →
Incyte Corporation Graham Number
Graham Number: $62.66d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Biogen Inc. (BIIB) $249.59
- Waters Corporation (WAT) $440.45
- Illumina, Inc. (ILMN) $192.82
- Quest Diagnostics Incorporated (DGX) $258.28
- Royalty Pharma plc (RPRX) $68.45
- West Pharmaceutical Services, Inc. (WST) $390.30
- United Therapeutics Corporation (UTHR) $554.73
- Tenet Healthcare Corporation (THC) $263.19
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5.14B | $4.24B | $3.7B | $3.39B | $2.99B |
| Operating income | $1.34B | $101.3M | $655.4M | $591.6M | $585.8M |
| Net income | $1.29B | $32.6M | $597.6M | $340.7M | $948.6M |
| EPSd | $6.41M | $154.9K | $2.65M | $1.52M | $4.27M |
| Operating cash flow | $1.41B | $335.3M | $496.5M | $969.9M | $749.5M |
| Capital expenditure | -$-58.87M | -$-86.26M | -$-47.49M | -$-77.83M | -$-181.01M |
| Free cash flow | $1.35B | $249.1M | $449M | $892.1M | $568.5M |
| Total assets | $6.96B | $5.44B | $6.78B | $5.84B | $4.93B |
| Total debt | $69.4M | $43.5M | $38.3M | $41.5M | $44.8M |
| Net debt | -$-3.03B | -$-1.64B | -$-3.18B | -$-2.91B | -$-2.01B |
| Total equity | $5.17B | $3.45B | $5.19B | $4.37B | $3.77B |
| Cash and short-term investments | $3.58B | $2.16B | $3.66B | $3.24B | $2.35B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5.14B | $4.24B | $3.7B | $3.39B | $2.99B |
| Cost of revenue | $372.1M | $312.1M | $255M | $207M | $151M |
| Gross profit | $4.77B | $3.93B | $3.44B | $3.19B | $2.84B |
| Research and development expenses | $2.05B | $2.61B | $1.63B | $1.59B | $1.46B |
| Selling, general and administrative expenses | $1.38B | $1.22B | $1.16B | $1B | $739.6M |
| Other expenses | $0.00 | -$-1.02M | $2.04M | $7.97M | $51.8M |
| Operating expenses | $3.43B | $3.83B | $2.79B | $2.6B | $2.25B |
| Cost and expenses | $3.8B | $4.14B | $3.04B | $2.8B | $2.4B |
| Interest income | $105.6M | $128.7M | $0.00 | $0.00 | $0.00 |
| Interest expense | $2.43M | $2.28M | $2.55M | $2.67M | $1.91M |
| Depreciation and amortization | $93.3M | $89.3M | $82.7M | $67.9M | $57.8M |
| Ebitda | $1.76B | $408.2M | $919.4M | $599.6M | $630.2M |
| Operating income | $1.34B | $101.3M | $655.4M | $591.6M | $585.8M |
| Total other income/expenses, net | $321.7M | $215.3M | $178.9M | -$-62.51M | -$-15.33M |
| Income before tax | $1.66B | $316.6M | $834.2M | $529.1M | $570.4M |
| Income tax expense | $377.8M | $284M | $236.6M | $188.5M | -$-378.14M |
| Net income | $1.29B | $32.6M | $597.6M | $340.7M | $948.6M |
| Weighted average shares outstanding | $195.2M | $207.1M | $223.6M | $222M | $220.4M |
| Weighted average diluted shares outstanding | $200.7M | $210.5M | $225.9M | $224M | $222.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $3.58B | $2.16B | $3.66B | $3.24B | $2.35B |
| Net receivables | $1.02B | $853.2M | $743.6M | $644.9M | $616.3M |
| Inventory | $101.1M | $58.9M | $63M | $42M | $27.9M |
| Total current assets | $5.02B | $3.24B | $4.65B | $4.09B | $3.12B |
| Property, plant and equipment, net | $758.4M | $794.2M | $777.1M | $765.6M | $751.5M |
| Goodwill and intangible assets | $250.1M | $269.4M | $279.1M | $284.8M | $306.4M |
| Long-term investments | $48M | $18.8M | $187.7M | $133.7M | $221.3M |
| Total non-current assets | $1.52B | $2.21B | $2.14B | $1.75B | $1.81B |
| Total assets | $6.96B | $5.44B | $6.78B | $5.84B | $4.93B |
| Accounts payable | $209.9M | $197.5M | $109.6M | $277.6M | $172.1M |
| Short-term debt | $10.2M | $10M | $9.12M | $11.4M | $13.2M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $1.52B | $1.64B | $1.24B | $1.16B | $854.3M |
| Long-term debt | $59.2M | $33.5M | $29.2M | $30.1M | $31.6M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $288.2M | $354.9M | $351.9M | $313.8M | $309M |
| Capital lease obligations | $44.7M | $43.5M | $38.3M | $41.5M | $44.8M |
| Total liabilities | $1.8B | $2B | $1.59B | $1.47B | $1.16B |
| Common stock | $200K | $190K | $220K | $220K | $220K |
| Retained earnings | $213.8M | -$-1.07B | $160.4M | -$-437.21M | -$-777.87M |
| Accumulated other comprehensive income (loss) | $25.5M | -$-13.12M | $13.1M | $15.1M | -$-19.45M |
| Total equity | $5.17B | $3.45B | $5.19B | $4.37B | $3.77B |
| Total investments | $530.8M | $489.1M | $630.4M | $421.2M | $512M |
| Total debt | $69.4M | $43.5M | $38.3M | $41.5M | $44.8M |
| Net debt | -$-3.03B | -$-1.64B | -$-3.18B | -$-2.91B | -$-2.01B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $1.29B | $32.6M | $597.6M | $340.7M | $948.6M |
| Depreciation and amortization | $93.3M | $89.3M | $82.7M | $67.9M | $57.8M |
| Stock-based compensation | $249.4M | $266.1M | $215.9M | $188.4M | $183M |
| Change in working capital | -$-527.16M | $138.2M | -$-248.65M | $198.8M | -$-14.57M |
| Accounts receivable | -$-170.77M | -$-111.59M | -$-98.68M | -$-28.58M | -$-134.31M |
| Inventory | -$-58.51M | -$-127.63M | -$-170.15M | -$-67.5M | -$-20.96M |
| Accounts payable | $6.56M | $88.2M | -$-167.94M | $105.4M | $73.3M |
| Net cash provided by operating activities | $1.41B | $335.3M | $496.5M | $969.9M | $749.5M |
| Investments in property, plant and equipment | -$-58.87M | -$-86.26M | -$-47.49M | -$-77.83M | -$-181.01M |
| Acquisitions, net | $0.00 | $0.00 | $47.5M | $710K | $181M |
| Net cash used for investing activities | -$-102.61M | $157.5M | -$-207.68M | -$-78.54M | -$-207.7M |
| Common stock issued | $221.8M | $49.3M | $35.8M | $61.1M | $58.6M |
| Common stock repurchased | -$-19.1M | -$-2B | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $101M | -$-2.02B | -$-20.03M | -$-790K | $6.18M |
| Net change in cash | $1.41B | -$-1.53B | $262.1M | $894M | $544.4M |
| Cash at end of period | $3.1B | $1.69B | $3.22B | $2.95B | $2.06B |
| Operating cash flow | $1.41B | $335.3M | $496.5M | $969.9M | $749.5M |
| Capital expenditure | -$-58.87M | -$-86.26M | -$-47.49M | -$-77.83M | -$-181.01M |
| Free cash flow | $1.35B | $249.1M | $449M | $892.1M | $568.5M |
Line items
Line items
Line items
About Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
- CEO
- William J. Meury
- Employees
- 2.84K
- Beta
- 0.76
Included in
Explore
Frequently asked questions
What is the intrinsic value of Incyte Corporation (INCY)?
Incyte Corporation (INCY) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is INCY undervalued?
INCY trades at a price of $114.63 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.